Study #2022-0774
A Phase II multicenter, open-label, single-dose escalation study of Asciminib monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
MD Anderson Study Status
Not Accepting
Treatment Agent
asciminib
Description
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Myelogenous Leukemia - Chronic Phase
Study phase:
Phase II
Physician name:
Koji Sasaki
Department:
Leukemia
For general questions about clinical trials:
1-877-934-6089
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.